News for Celcuity Inc. (CELC)

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday. Shares of Northrop Grumman Corporation NOC shares fell ...

While Donald Trump spared pharma companies from his tariff announcement last week, he revealed yesterday plans to announce tariffs on the industry soon.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday. Shares of The Greenbrier Companies, Inc. GBX fell sh...

The following slide deck was published by Celcuity Inc.

Discover Celcuity's Q4 2024 insights: gedatolisib's promising trials for breast cancer, $2B market potential, and key 2025 milestones.

Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsApoorva Chaloori - ICR Healthcare, Investor...

**media[574560]**

PR NewswireVANCOUVER, BC, Feb. 27, 2025 USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US

MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for on

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. A speculative yet undervalued investment opportunity.

On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a significant transaction involving Celcuity Inc (CELC), reducing its holdings by 426,68

Overview of the Recent Transaction On December 31, 2024, Baker Bros. Advisors LP made a strategic move by acquiring an additional 803,575 shares of Celcuity Inc

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Thursday. Shares of Neumora Therapeutics, Inc. NMRA fell shar...

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. Shares of Mama’s Creations Inc MAMA fell sharply in to...

Shares of Mitek Systems, Inc. MITK rose sharply in today's pre-market trading after reporting better-than-expected fourth-quarter results. Mitek Systems report...

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS

Celcuity Inc. (NASDAQ:CELC) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ETCompany ParticipantsApoorva Chaloori - ICR Westwicke, Investor...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Read more on CELC stock here.

Net Loss: $23.7 million or $0.62 per share for Q2 2024, compared to $14.6 million or $0.66 per share for Q2 2023.Non-GAAP Adjusted Net Loss: $22.2 million or $